A number of firms have modified their ratings and price targets on shares of Evolent Health (NYSE: EVH) recently:

  • 10/9/2017 – Evolent Health was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Evolent Health, Inc. is involved in the healthcare delivery and payment markets. The company provides technology-enabled services platform for providers to transition their organization in value-based payment models. Evolent Health, Inc. is based in Arlington, Virginia. “
  • 10/6/2017 – Evolent Health had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $29.00 price target on the stock, down previously from $33.00.
  • 10/6/2017 – Evolent Health had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $32.00 price target on the stock.
  • 10/2/2017 – Evolent Health was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Evolent Health, Inc. is involved in the healthcare delivery and payment markets. The company provides technology-enabled services platform for providers to transition their organization in value-based payment models. Evolent Health, Inc. is based in Arlington, Virginia. “
  • 9/26/2017 – Evolent Health had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $25.00 price target on the stock, down previously from $35.00. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 9/20/2017 – Evolent Health had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $30.00 price target on the stock.
  • 9/19/2017 – Evolent Health is now covered by analysts at KeyCorp. They set an “overweight” rating and a $23.00 price target on the stock.
  • 9/6/2017 – Evolent Health had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $28.00 price target on the stock.
  • 8/18/2017 – Evolent Health had its “buy” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 8/18/2017 – Evolent Health was given a new $32.00 price target on by analysts at Leerink Swann. They now have a “buy” rating on the stock.
  • 8/12/2017 – Evolent Health was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Shares of Evolent Health, Inc (EVH) traded up 0.452% during midday trading on Wednesday, reaching $16.675. 492,990 shares of the company’s stock traded hands. The stock has a 50 day moving average of $17.39 and a 200-day moving average of $17.39. The stock’s market cap is $1.24 billion. Evolent Health, Inc has a 52-week low of $14.50 and a 52-week high of $27.50.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Monday, August 7th. The technology company reported ($0.13) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.13). Evolent Health had a negative return on equity of 6.44% and a negative net margin of 17.57%. The company had revenue of $107.30 million for the quarter, compared to analysts’ expectations of $104.45 million. During the same quarter last year, the business earned ($0.20) earnings per share. Evolent Health’s revenue was up 89.9% on a year-over-year basis. On average, equities research analysts expect that Evolent Health, Inc will post ($0.40) EPS for the current year.

In related news, CEO Frank J. Williams sold 16,300 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $23.73, for a total value of $386,799.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Thomas Peterson III sold 40,540 shares of the firm’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $26.00, for a total value of $1,054,040.00. The disclosure for this sale can be found here. Insiders sold 62,840 shares of company stock worth $1,588,679 in the last 90 days. 8.79% of the stock is owned by company insiders.

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.